Analysis of ferroptosis hub genes in the peripheral blood of patients with multiple system atrophy andtheir drug targets by whole genome sequencing
10.12007/j.issn.0258-4646.2024.09.010
- VernacularTitle:全基因测序探索多系统萎缩患者外周血液中铁死亡相关核心基因及其药物靶点
- Author:
Ya HAN
1
;
Zheng ZHANG
;
Yaheng ZHANG
Author Information
1. 河南科技大学第二附属医院神经内科,河南 洛阳 471003
- Keywords:
multiple system atrophy;
blood;
ferroptosis;
competing endogenous RNA;
biomarker
- From:
Journal of China Medical University
2024;53(9):821-826
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the differentially expressed ferroptosis genes in the blood of patients with multiple system atrophy(MSA),and to find a new direction for diagnosis and treatment.Methods Blood samples were collected from patients with MSA and sub-jected to high-throughput whole-genome sequencing analysis.The data were processed,and differentially expressed lncRNA and mRNAs genes were screened.Ferroptosis genes were further screened for gene ontology(GO)enrichment analysis and protein-protein interaction network construction.The MCODE plugin in Cytoscape was used to screen key gene modules.A ferroptosis competing endogenous RNA(ceRNA)network was constructed,and gene-drug association analysis was performed on the mRNAs genes in the network.Results A total of 34 ferroptosis mRNAs genes were identified.Hub modules and ceRNA network construction revealed that both networks con-tained MAPK14 and MTF1.Predictive drug gene analysis revealed that MAPK14 had numerous drug treatment targets.PCR results showed that MAPK14 mRNA expression was significantly upregulated in MSA group compared with healthy control group.Conclusion Ferroptosis genes are differentially expressed in the peripheral blood of patients with MSA,and these differentially expressed genes may be related to abnormal lipid metabolism and oxidative stress pathways.Among these,the hub gene MAPK14may play an important role in the regulatory network and is an excellent potential drug therapeutic target and diagnostic marker.
